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Abstract 
Theranostics is a multidisciplinary journal that publishes innovative and original research papers 
reflecting the field of molecular imaging, molecular therapeutics, multifunctional nanoparticle 
platforms, image-guided therapy, and translational nanomedicine. A broad spectrum of bio-
medical research that can be applied to future theranostic applications is encouraged. 
Key words: molecular imaging, molecular therapy, theranostics, nanomedicine 
 
It  is  my  great  pleasure  to  introduce  the  new 
journal Theranostics. Theranostics is a concept that was 
originally raised to refer to the efforts of integrating 
imaging and therapy. As an emerging interdiscipline, 
it is related to but different from traditional imaging 
and therapeutics. It embraces the efforts of utilizing 
multiple techniques to arrive at a comprehensive im-
aging/therapy  regimen.  More  recently,  there  is  a 
trend of tangling those efforts with emerging materi-
als  science  and  nanotechnologies,  in  an  attempt  to 
develop novel platforms and methodologies to tackle 
practical  issues  in  clinics.  Work  in  this  area  can  be 
significant  for  being  cutting-edge  and  potentially 
translatable, and the community has grown up rap-
idly.  
Unfortunately,  most  existing  journals  in  the 
fields of imaging or therapy, such as Journal of Nu-
clear  Medicine,  Magnetic  Resonance  Imaging  and 
Radiology, etc., focus more on single modality imag-
ing and do not necessarily encourage comprehensive 
theranostic  studies.  On  the  other  hand,  materials 
based  journals,  such  as  Nano  Letters,  SMALL  and 
ACS  Nano,  have  diversified  interests  in  nanotech-
nologies,  and  are  not  particularly  addressing  the 
clinical relevance of the research work. Launching a 
journal on this topic is therefore significant for filling 
the gap and promoting the concept of theranostics. 
The aim of Theranostics is to provide a forum for 
the exchange of clinical and scientific information for 
the  diagnostic  and  therapeutic  molecular  and  nano 
medicine community and allied professions involved 
in  the  efforts  of  integrating  molecular  imaging  and 
molecular therapy. Theranostics is a multidisciplinary 
journal  that  publishes  innovative  and  original  re-
search papers reflecting the field of molecular imag-
ing, molecular therapeutics, multifunctional nanopar-
ticle  platforms,  image-guided  therapy,  and  transla-
tional nanomedicine. A broad spectrum of biomedical 
research that can be applied to future theranostic ap-
plications is encouraged. In addition to primary re-
search, Theranostics also publishes reviews, news, and 
commentary to understand and bridge the gap among 
the laboratory, clinic, and biotechnology industries. 
Note  that  in  some  cases  theranostics  is  also 
spelled as theragnostics. Keyword search of PubMed 
as of January 7, 2010 found 95 items for “theranostic”, 
63 items for “theranostics”, 29 items for “theragnos-
tic” and 21 items for “theragnostics”.  
This  journal  will  be  published  using  an  Open 
Access publishing model, which means that accepted 
papers will be freely and immediately available on the 
journal’s website without any access barriers. It is our 
belief that the Open Access model will become a ma-
jor force in scientific publishing in the near future, and Theranostics 2011, 1 
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we hope that Theranostics will be a leading journal in 
this new movement. 
In both the review process and the production 
process we will aim for the highest possible quality 
and  speed.  Papers  in  the  journal  will  be  rigorously 
peer-reviewed.  We  have  already  assembled  a 
first-rate Editorial Board, and we plan to continuously 
strengthen it in terms of academic authority, specialty 
balance,  geographic  scope,  junior  involvement,  and 
individual  productivity.  Each  board  member  will 
make  active  contributions  and  be  evaluated  yearly 
with routine adjustment for maximum benefit of the 
journal. Special Issues will be organized to make well 
defined contributions to the literature in key areas of 
research. 
In  opening  up  this  new  journal,  we  are  very 
pleased and thankful to receive the brilliant contribu-
tions and supports from many distinguished authors 
and organizations all over the world. I thank the pio-
neer authors, all members of the founding Editorial 
Board, and members of publishing team in Ivyspring 
International Publisher for their efforts in providing 
significant supports and suggestions and organizing 
the Theranostics from ground zero. 
We are confident that Theranostics will soon es-
tablish itself as a highly reputable journal, due to the 
fact that it is the  first journal in this important and 
emerging  field,  the  advantages  of  its  Open  Access 
publishing  model,  comprehensive  coverage,  novel 
features, and high academic standards. Please feel free 
to contact the Editor-in-Chief if you have any ideas or 
suggestions. 
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